NAYA BIOSCIENCES INC. - COMMON STOCK

NAYA Biosciences Announces Pricing of $9.5 Million Public Offering 

13 1 2025 08:15:44 提供 Nasdaq GlobeNewswire

NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody

06 1 2025 07:30:00 提供 Nasdaq GlobeNewswire

NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

31 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

24 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences

21 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)

14 10 2024 08:18:20 提供 Nasdaq GlobeNewswire

INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA

14 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

INVO Reports Record First Quarter 2024 Financial Results

15 5 2024 15:15:00 提供 Nasdaq GlobeNewswire

INVO Reports Fourth Quarter and Full Year 2023 Financial Results

16 4 2024 15:59:29 提供 Nasdaq GlobeNewswire